Literature DB >> 16358364

Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism.

Francesca Fallarino1, Paolo Puccetti.   

Abstract

A series of recent studies, including an article in this issue of the European Journal of Immunology, have demonstrated that the administration of CpG-rich oligodeoxynucleotides (CpG-ODN) in experimental settings may lead to the activation of the immunosuppressive pathway of tryptophan catabolism, depending on several factors, including the route of CpG-ODN administration. These studies call attention to the need for a careful evaluation of the modalities of inclusion of CpG-ODN in vaccines for human use. At the same time, these studies may offer novel opportunities for use of CpG-ODN as immunosuppressive agents and may also lead to an improved understanding of the cellular events mediated by Toll-like receptor 9 signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16358364     DOI: 10.1002/eji.200535667

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  18 in total

Review 1.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Alexander Eggermont; Catherine Sautès-Fridman; Eric Tartour; Eugene P Kennedy; Michael Platten; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

2.  Activation of the STING adaptor attenuates experimental autoimmune encephalitis.

Authors:  Henrique Lemos; Lei Huang; Phillip R Chandler; Eslam Mohamed; Guilherme R Souza; Lingqian Li; Gabriela Pacholczyk; Glen N Barber; Yoshihiro Hayakawa; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2014-05-05       Impact factor: 5.422

3.  Antitumor activity mediated by CpG: the route of administration is critical.

Authors:  Yanyan Lou; Chengwen Liu; Gregory Lizée; Weiyi Peng; Chunyu Xu; Yang Ye; Brian A Rabinovich; Yared Hailemichael; Alexander Gelbard; Dapeng Zhou; Willem W Overwijk; Patrick Hwu
Journal:  J Immunother       Date:  2011-04       Impact factor: 4.456

4.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

5.  IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo.

Authors:  Young H Kim; Beom K Choi; Woo J Kang; Kwang H Kim; Sang W Kang; Andrew L Mellor; David H Munn; Byoung S Kwon
Journal:  J Leukoc Biol       Date:  2009-02-13       Impact factor: 4.962

6.  Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Authors:  Stefan Nierkens; Martijn H den Brok; Thijs Roelofsen; Jori A L Wagenaars; Carl G Figdor; Theo J Ruers; Gosse J Adema
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

7.  High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway.

Authors:  Claudia Volpi; Francesca Fallarino; Maria T Pallotta; Roberta Bianchi; Carmine Vacca; Maria L Belladonna; Ciriana Orabona; Antonella De Luca; Louis Boon; Luigina Romani; Ursula Grohmann; Paolo Puccetti
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 8.  Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.

Authors:  Adriano Boasso; Gene M Shearer
Journal:  Clin Immunol       Date:  2007-10-03       Impact factor: 3.969

9.  The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation.

Authors:  Wei Chen; Xueqing Liang; Amanda J Peterson; David H Munn; Bruce R Blazar
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

Review 10.  Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

Authors:  Stefan Löb; Alfred Königsrainer; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.